|
Jan 6
|
Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
|
|
Jan 3
|
Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration
|
|
Jan 2
|
Innovent and Roche link on lung cancer therapy development
|
|
Jan 1
|
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
|